Anal Cancer and Anal Intraepithelial Neoplasia Risk Among Patients Treated for HPV-Related Gynecological Diseases-A Systematic Review

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Jul 14

PMID 37445251

Authors

Michal Brzezinski

Maciej Stukan

Affiliations

Soon will be listed here.

Abstract

Background: The most important causative agent of neoplasms in the anogenital area is the human papillomavirus (HPV). Due to the anatomical proximity of the genital and anus area and the ease with which HPV infection is transmitted, it seems that patients after the treatment of HPV-related gynecological diseases may have an increased risk of developing a second HPV-related neoplasm anal cancer. The aim of this study was to determine the risk of anal intraepithelial neoplasia (AIN) and anal cancer (AC) among patients after the treatment of HPV-related gynecological diseases.

Methods: We conducted a comprehensive review of the available literature from multiple databases. The study was performed following and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 guidelines. Moreover, we assessed the quality of each study using QUADAS-2.

Results: Twenty-five studies were included in the final analysis. Patients after the treatment of HPV-related gynecological diseases have a significantly higher risk of AC (mean standardized incidence ratio (SIR) = 5.387, mean incidence risk (IR) = 0.096%, mean IR per 100,000 person-years = 10.37) and AIN (mean IR = 23.683%) compared to the population risk.

Conclusions: patients with HPV-related gynecological diseases should constitute a group for which an appropriate primary and secondary screening for AC should be introduced.

Citing Articles

Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment.

English K World J Exp Med. 2024; 14(3):98525.

PMID: 39312693 PMC: 11372733. DOI: 10.5493/wjem.v14.i3.98525.

Risk Factors for the Anal and Oral Human Papillomavirus (HPV) Infections among Women with Severe Cervical Lesions: A Prospective Case-Control Study.

Dzundova M, Sehnal B, Zikan M, Kocian R, Dubova O, Hubka P Biomedicines. 2023; 11(12).

PMID: 38137404 PMC: 10741157. DOI: 10.3390/biomedicines11123183.

References

Kelly H, Chikandiwa A, Vilches L, Palefsky J, de Sanjose S, Mayaud P . Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis. Lancet HIV. 2020; 7(4):e262-e278. DOI: 10.1016/S2352-3018(19)30434-5. View

de Martel C, Plummer M, Vignat J, Franceschi S . Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017; 141(4):664-670. PMC: 5520228. DOI: 10.1002/ijc.30716. View

Papatla K, Halpern M, Hernandez E, Brown J, Benrubi D, Houck K . Second primary anal and oropharyngeal cancers in cervical cancer survivors. Am J Obstet Gynecol. 2019; 221(5):478.e1-478.e6. DOI: 10.1016/j.ajog.2019.05.025. View

Waxman A, Chelmow D, Darragh T, Lawson H, Moscicki A . Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet Gynecol. 2012; 120(6):1465-71. PMC: 4054813. DOI: 10.1097/aog.0b013e31827001d5. View

Chaturvedi A, Engels E, Gilbert E, Chen B, Storm H, Lynch C . Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst. 2007; 99(21):1634-43. DOI: 10.1093/jnci/djm201. View

Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki H . Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013; 8(7):e68329. PMC: 3714284. DOI: 10.1371/journal.pone.0068329. View

Munoz N, Manalastas Jr R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009; 373(9679):1949-57. DOI: 10.1016/S0140-6736(09)60691-7. View

Neumann F, Jegu J, Mougin C, Pretet J, Guizard A, Lapotre-Ledoux B . Risk of second primary cancer after a first potentially-human papillomavirus-related cancer: A population-based study. Prev Med. 2016; 90:52-8. DOI: 10.1016/j.ypmed.2016.06.041. View

Jakobsson M, Pukkala E, Paavonen J, Tapper A, Gissler M . Cancer incidence among Finnish women with surgical treatment for cervical intraepithelial neoplasia, 1987-2006. Int J Cancer. 2010; 128(5):1187-91. DOI: 10.1002/ijc.25428. View

10.

Saraiya M, Unger E, Thompson T, Lynch C, Hernandez B, Lyu C . US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015; 107(6):djv086. PMC: 4838063. DOI: 10.1093/jnci/djv086. View

11.

Deshmukh A, Suk R, Shiels M, Sonawane K, Nyitray A, Liu Y . Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015. J Natl Cancer Inst. 2019; 112(8):829-838. PMC: 7825484. DOI: 10.1093/jnci/djz219. View

12.

Stier E, Goldstone S, Einstein M, Jay N, Berry J, Wilkin T . Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS. 2012; 27(4):545-51. PMC: 3759510. DOI: 10.1097/QAD.0b013e32835a9b16. View

13.

Lin C, Slama J, Gonzalez P, Goodman M, Xia N, Kreimer A . Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infect Dis. 2019; 19(8):880-891. PMC: 6656696. DOI: 10.1016/S1473-3099(19)30164-1. View

14.

Jacot-Guillarmod M, Balaya V, Mathis J, Hubner M, Grass F, Cavassini M . Women with Cervical High-Risk Human Papillomavirus: Be Aware of Your Anus! The ANGY Cross-Sectional Clinical Study. Cancers (Basel). 2022; 14(20). PMC: 9600245. DOI: 10.3390/cancers14205096. View

15.

Dehlendorff C, Baandrup L, Kjaer S . Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers. J Natl Cancer Inst. 2020; 113(7):869-874. PMC: 8246827. DOI: 10.1093/jnci/djaa209. View

16.

Kjaer S, Dehlendorff C, Belmonte F, Baandrup L . Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J Natl Cancer Inst. 2021; 113(10):1329-1335. PMC: 8486335. DOI: 10.1093/jnci/djab080. View

17.

Grulich A, Poynten I, Machalek D, Jin F, Templeton D, Hillman R . The epidemiology of anal cancer. Sex Health. 2012; 9(6):504-8. DOI: 10.1071/SH12070. View

18.

Wei L, Xie X, Liu J, Zhao Y, Chen W, Zhao C . Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up. Vaccine. 2018; 37(27):3617-3624. DOI: 10.1016/j.vaccine.2018.08.009. View

19.

Matsuo K, Blake E, Machida H, Mandelbaum R, Roman L, Wright J . Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. Gynecol Oncol. 2018; 150(3):501-508. PMC: 7521078. DOI: 10.1016/j.ygyno.2018.07.016. View

20.

Hemminki K, Jiang Y, Dong C . Second primary cancers after anogenital, skin, oral, esophageal and rectal cancers: etiological links?. Int J Cancer. 2001; 93(2):294-8. DOI: 10.1002/ijc.1319. View